Skip to main
NKTX

Nkarta, Inc. (NKTX) Stock Forecast & Price Target

Nkarta, Inc. (NKTX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nkarta Inc. is strategically enhancing patient enrollment in its clinical trials through the successful reincorporation of standardized lymphodepletion with fludarabine. The company is positioned as an attractive investment opportunity within the emerging NK cell therapy market, which offers a competitive edge over conventional CAR-T therapies due to its biological and logistical advantages. Furthermore, Nkarta's innovative approach in utilizing engineered NK cells to treat cancer signifies a pivotal advancement in the development of cell-based therapies, underscoring its potential for sustained growth and success in the evolving biopharmaceutical landscape.

Bears say

Nkarta Inc. is currently facing a challenging financial outlook, primarily driven by a significantly reduced research and development (R&D) spend, which dropped 14% sequentially, indicating potential constraints in advancing their clinical projects. The company’s decision to amend its NKX019 lymphodepletion regimen by reincorporating fludarabine is anticipated to limit the effectiveness of initial trial conclusions, thereby raising concerns over the robustness of their therapy's efficacy. Furthermore, management's choice to delay the preliminary year-end 2025 data disclosure in favor of a more comprehensive set of results at a FY26 medical conference suggests that the forthcoming data may not adequately alleviate investor uncertainty amid perceived inconclusiveness stemming from the recent protocol changes.

Nkarta, Inc. (NKTX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nkarta, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nkarta, Inc. (NKTX) Forecast

Analysts have given Nkarta, Inc. (NKTX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Nkarta, Inc. (NKTX) has a Strong Buy consensus rating as of Jan 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nkarta, Inc. (NKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.